Johnson & Johnson is up ~45% in 2025, with robust execution and financials, but current valuations limit further upside. JNJ's organic growth and margin expansion remain moderate, with recent gains ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果